Targacept Wows Wall Street With Phase IIb Depression Data

Targacept wowed analysts with newly released Phase IIb data for depression drug candidate TC-5214, making a big splash at a meeting of the Society for Neuroscience and causing shares in the company to shoot up 16percent Friday. (BioWorld Today)